Review board rules against Osteo-Bi Flex ad claims
NEW YORK NBTY lost its appeal to The National Advertising Review Board, the board announced Monday, which recommended that the company discontinue use of “Double Strength” and “Triple Strength” descriptors on Osteo-Bi Flex product packaging and in other advertising unless those terms are qualified to indicate that they refer to the level of key ingredients in each individual caplet and does not imply greater product performance or efficacy.
The appeal originated from a monitoring case opened by the National Advertising Division of the Council of Better Business Bureaus. As part of NAD’s routine monitoring program, NAD requested substantiation for certain claims made by Rexall Sundown (owned by NBTY) for its Osteo Bi-Flex dietary supplement.
The panel also recommends that Rexall remove its claims that the Boswellia serrata extract in 5-LOXIN is 10 times more concentrated than typical Boswellia serrata extracts unless those claims are presented in a context that does not imply that the increased concentration results in increased product performance or efficacy.
Intlekofer resigns at Nutrition 21
PURCHASE, N.Y. Nutrition 21 on Friday announced that Paul Intlekofer has resigned as chief executive officer and as a director of the company.
“We thank Paul for the many years of service that he has given to the company, and appreciate his desire to work in the vicinity of his home in Baltimore,” stated John Gutfreund, the company’s chairman. “He will serve as a consultant to the company.”
Gerard Butler and Michael Fink have been elected to serve as interim co-chief executive officers.
Both Butler and Fink were previously executives at Prestige Brands Holdings and Block Drug Company.
FDA launches updated Web site
ROCKVILLE, Md. The Food and Drug Administration this week unveiled a new Web site—a Web site that features a “layered” approach that enables FDA surfers to find information quickly.
“Structure is improved to provide for easy scanning; content is presented in plain language to make it more understandable,” the FDA stated in introducing the new Web format. “In a nutshell, we listened to you. We tested the usability of our Web site by asking our key audiences. We sampled more than 188 consumers, healthcare professionals and industry representatives and other audiences. … This usability data pointed us to improvements to make the home page easier and more satisfying to use.”